Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Would you start a GLP 1 receptor agonist for treatment of Type 2 diabetes in patients with remote family history of medullary thyroid cancer without genetic testing?
Related Questions
How do you titrate the dose of an ACE inhibitor in a patient with type 1 diabetes mellitus who is normotensive but has moderately increased albuminuria?
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
Do you foresee any added benefit of triple agonist therapy (GLP-1, GIP and glucagon) for glycemic control in patients with Type 1 diabetes mellitus?
How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
Is the combination of SGLT2i and GLP 1 R agonist therapy contraindicated in patients who develop an episode of euglycemic DKA?
How do you approach insulin adjustments for a patient with type 1 diabetes who is not on an insulin pump and who has higher blood glucose levels in the late luteal phase of the menstrual cycle, when glucose levels are expected to rise?
What is the clinical significance of a low c-peptide and insulin level when glucose levels are normal?
In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?
Does injectable semaglutide have a higher glucose-lowering efficiency than oral semaglutide?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
